Di Minno et al. enrolled 25 patients with familial hypercholesterolemia and observed improved endothelial function after 12 weeks of PCSK9 inhibitor treatment in the administration regime every 14 days. This evidence concerns the gene PCSK9 and familial hypercholesterolemia.